Filtered By:
Cancer: Adenocarcinoma
Therapy: Cancer Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 21 results found since Jan 2013.

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles.
Authors: Strand MS, Krasnick BA, Pan H, Zhang X, Bi Y, Brooks C, Wetzel C, Sankpal N, Fleming T, Goedegebuure SP, DeNardo DG, Gillanders WE, Hawkins WG, Wickline SA, Fields RC Abstract Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation. However, no direct RAS inhibitors exist for cancer therapy. Furthermore, the delivery of therapeutic agents of any kind to PDAC in particular has been hindered by the extensive desmoplasia and resultant drug delivery challenges that accompanies these tumors. Small interfer...
Source: Oncotarget - August 17, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3 BASIC SCIENCE
CONCLUSIONS In our study, we emphasized that siRNA interference might represent a productive platform for further research in order to investigate whether a new regimen in the treatment of multiresistant non-small-cell lung cancer could be established in vivo in the context of a multimodal cancer therapy.
Source: European Journal of Cardio-Thoracic Surgery - October 10, 2014 Category: Cardiovascular & Thoracic Surgery Authors: Stoleriu, M. G., Steger, V., Mustafi, M., Michaelis, M., Cinatl, J., Schneider, W., Nolte, A., Kurz, J., Wendel, H. P., Schlensak, C., Walker, T. Tags: Lung - cancer, Lung - transplantation, Mediastinum, Pleura, Cardiac - pharmacology, Lung - basic science Source Type: research

Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line.
CONCLUSION: Our results suggest that the bach1 can be considered as a potent adjuvant in breast cancer therapy. PMID: 28092843 [PubMed - as supplied by publisher]
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - January 12, 2017 Category: Drugs & Pharmacology Authors: Aletaha M, Mansoori B, Mohammadi A, Fazeli M, Baradaran B Tags: Biomed Pharmacother Source Type: research

Therapeutic effects of bach1 siRNA on human breast adenocarcinoma cell line
Conclusion Our results suggest that the bach1 can be considered as a potent adjuvant in breast cancer therapy.
Source: Biomedicine and Pharmacotherapy - January 13, 2017 Category: Drugs & Pharmacology Source Type: research

Targeting A549 lung adenocarcinoma cell growth and invasion with protease‑activated receptor‑1 siRNA.
In conclusion, the present study demonstrated that the progression of A549 cells is able to be inhibited by knockdown of PAR1 expression. Efficient delivery of the specific siRNA targeting PAR1 may be used for further study in clinical cancer therapy. PMID: 24604247 [PubMed - as supplied by publisher]
Source: Molecular Medicine - March 6, 2014 Category: Molecular Biology Authors: Wu Z, Zeng Y, Zhong M, Wang B Tags: Mol Med Rep Source Type: research

Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention
In conclusion, osmotic burst of inflated complement-damaged cells may occur, but these bursts are most likely a consequence of metabolic collapse of the cell rather than the cause of cell death. The Complement Cell Death Mediator: A Concerted Action of Toxic Moieties Membrane pores caused by complement were first visualized by electron microscopy on red blood cell membranes as large ring structures (22). Similar lesions were viewed on E. coli cell walls (23). Over the years, ample information on the fine ultrastructure of the MAC that can activate cell death has been gathered (24) and has been recently further examined (...
Source: Frontiers in Immunology - April 9, 2019 Category: Allergy & Immunology Source Type: research

Abstract 4054: Elongation factor-2 kinase (eEF-2K) promotes cell invasion and epithelial mesenchymal transition through regulation of TG2-mediated signaling in human pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) accounts for the majority of pancreatic cancer (PaCa) cases and is currently uncurable with poor prognosis/survival rates (∼4% 5-year survival). The extensive local tumor invasion, early metastasis/systemic dissemination and resistance to existing cancer therapies are the major characteristics of PaCa and the impediment to effective cure of this disease. Although PaCa has a well-defined spectrum of highly oncogenic lesions (e.g, mutations in K-RAS, p53, p16ink4a, and SMAD4/DPC4), effective therapies have not yet been developed. Therefore, novel molecular targets-based therapeutic s...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Ashour, A. A., Alpay, S. N., Gurbuz, N., Abdel-Aziz, A.-A. H., Mansour, A. M., Ozpolat, B. Tags: Tumor Biology Source Type: research

Down-regulation of anti-apoptotic genes in tumor cell lines is facilitated by suppression of OCT4B1
Conclusions It may possibly be concluded that suppression of OCT4B1 can lead to apoptosis in tumor cell lines and this is at least facilitated via down-regulation of examined anti-apoptotic genes. Accordingly, suppression of OCT4B1 may probably be considered as useful tool in cancer therapy and research.
Source: Advances in Medical Sciences - May 10, 2016 Category: Biomedical Science Source Type: research

Ribosomal protein S3 selectively affects colon cancer growth by modulating the levels of p53 and lactate dehydrogenase.
In this study, we aim at determining the expression levels of RPS3 in a colon cancer cell line Caco-2 compared to a normal colon mucosa cell line NCM-460 and study the effects of targeting this protein by siRNA on cellular behavior. RPS3 was found to be expressed in both cell lines. However, siRNA treatment showed a more protruding effect on Caco-2 cells compared to NCM-460 cells. RPS3 knockdown led to a significant decrease in the proliferation, survival, migration and invasion and an increase in the apoptosis of Caco-2 cells. Western blot analysis demonstrated that these effects correlated with an increase in the level o...
Source: Molecular Biology Reports - August 2, 2020 Category: Molecular Biology Authors: Alam E, Maaliki L, Nasr Z Tags: Mol Biol Rep Source Type: research

TrkB/BDNF Signaling Could Be a New Therapeutic Target for Pancreatic Cancer
CONCLUSION: TrkB/BDNF signaling may be a new therapeutic target for PDAC. Therapies targeting TrkB/BDNF signaling may be a conclusive cancer therapy for refractory solid cancer.PMID:34281873 | DOI:10.21873/anticanres.15205
Source: Cell Research - July 20, 2021 Category: Cytology Authors: Yasuhiro Oyama Shinjiro Nagao Lin Na Kosuke Yanai Masayo Umebayashi Katsuya Nakamura Shuntaro Nagai Akiko Fujimura Akio Yamasaki Kazunori Nakayama Takashi Morisaki Hideya Onishi Source Type: research

Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.
CONCLUSION: SeV/dF/FIR showed strong tumor growth suppression with no significant side effects in an animal xenograft model, thus SeV/dF/FIR is potentially applicable for future clinical cancer treatment. PMID: 24764668 [PubMed - in process]
Source: World Journal of Gastroenterology : WJG - April 21, 2014 Category: Gastroenterology Authors: Matsushita K, Shimada H, Ueda Y, Inoue M, Hasegawa M, Tomonaga T, Matsubara H, Nomura F Tags: World J Gastroenterol Source Type: research

Abstract 5203: Long non-coding RNA H19 as a novel therapeutic target for pancreatic cancer
Long non-coding RNAs (lncRNAs), non-protein coding transcripts longer than 200 nucleotides, have been recently reported to play important roles in carcinogenesis and cancer metastasis through epigenetic regulation. In the present study, we examined the expression levels and roles of lncRNA in pancreatic cancer to elucidate whether lncRNA could be a novel candidate for pancreatic cancer therapy. First, we injected PANC-1 and PK-45H, pancreatic ductal adenocarcinoma cells into the spleens of NOD/Shi-scid, IL-2Rγnull (NOG) mice, and then established novel cell lines from liver and lung metastatic nodules. Microarray analysis...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Yoshimura, H., Matsuda, Y., Suzuki, T., Naito, Z., Ishiwata, T. Tags: Molecular and Cellular Biology Source Type: research

The protein ERp57 contributes to EGF receptor signaling and internalization in MDA‐MB‐468 breast cancer cells
Abstract The disulfide isomerase ERp57 is a soluble protein mainly located in the endoplasmic reticulum, where it acts in the quality control of newly synthesized glycoproteins, in association with calreticulin and calnexin. It has been also detected in other cell compartments, such as the cytosol, the plasma membrane and the nucleus. In these locations it is implicated in various processes, participating in the rapid response to calcitriol, modulating the activity of STAT3 and being requested for the pre‐apoptotic exposure of calreticulin on the plasma membrane. In the present work, the involvement of ERp57 in the activ...
Source: Journal of Cellular Biochemistry - May 20, 2013 Category: Biochemistry Authors: Gaucci Elisa, Altieri Fabio, Carlo Turano, Chichiarelli Silvia Tags: Article Source Type: research

Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.
In this study, the combination treatment of NSC109555 plus GEM demonstrated strong synergistic antitumour effect in four pancreatic cancer cells (MIA PaCa-2, CFPAC-1, Panc-1 and BxPC-3). In addition, the GEM/NSC109555 combination significantly increased the level of intracellular reactive oxygen species (ROS), accompanied by induction of apoptotic cell death. Inhibition of ROS generation by N-acetyl cysteine (NAC) significantly reversed the effect of GEM/NSC109555 in apoptosis and cytotoxicity. Furthermore, genetic knockdown of CHK2 by siRNA enhanced GEM-induced apoptotic cell death. These findings suggest that inhibition ...
Source: J Cell Mol Med - July 16, 2013 Category: Molecular Biology Authors: Duong HQ, Hong YB, Kim JS, Lee HS, Yi YW, Kim YJ, Wang A, Zhao W, Cho CH, Seong YS, Bae I Tags: J Cell Mol Med Source Type: research

Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine
In this study, the combination treatment of NSC109555 plus GEM demonstrated strong synergistic antitumour effect in four pancreatic cancer cells (MIA PaCa‐2, CFPAC‐1, Panc‐1 and BxPC‐3). In addition, the GEM/NSC109555 combination significantly increased the level of intracellular reactive oxygen species (ROS), accompanied by induction of apoptotic cell death. Inhibition of ROS generation by N‐acetyl cysteine (NAC) significantly reversed the effect of GEM/NSC109555 in apoptosis and cytotoxicity. Furthermore, genetic knockdown of CHK2 by siRNA enhanced GEM‐induced apoptotic cell death. These findings suggest that...
Source: Journal of Cellular and Molecular Medicine - July 16, 2013 Category: Molecular Biology Authors: Hong‐Quan Duong, Young Bin Hong, Jung Soon Kim, Hee‐Seok Lee, Yong Weon Yi, Yeon Jeong Kim, Antai Wang, Wenjing Zhao, Chi Heum Cho, Yeon‐Sun Seong, Insoo Bae Tags: Original Article Source Type: research